Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis.

Systemic-onset juvenile chronic arthritis (SoJCA) is associated with high levels of circulating interleukin-6 (IL-6) and is frequently complicated by severe microcytic anemia whose pathogenesis is unclear. Therefore, we studied 20 consecutive SoJCA patients with hemoglobin (Hb) levels <12 g/dL, evaluating erythroid progenitor proliferation, endogenous erythropoietin production, body iron status, and iron supply for erythropoiesis. Hb concentrations ranged from 6.5 to 11.9 g/dL. Hb level was directly related to mean corpuscular volume (r = .82, P < .001) and inversely related to circulating transferrin receptor (r = -.81, P < .001) suggesting that the severity of anemia was directly proportional to the degree of iron-deficient erythropoiesis. Serum ferritin ranged from 18 to 1,660 microgram/L and was unrelated to Hb level. Bone marrow iron stores wore markedly reduced in the three children investigated, and they also showed increased serum transferrin receptor and normal-to-high serum ferritin. All 20 patients had elevated IL-6 levels and normal in vitro growth of erythroid progenitors. Endogenous erythropoietin (epo) production was appropriate for the degree of anemia as judged by both the observed to predicted log (serum epo) ratio 10.95 +/- 0.12) and a comparison of the serum epo-Hb regression found in these subjects with that of thalassemia patients. Multiple regression analysis showed that serum transferrin receptor was the parameter most closely related to hemoglobin concentration: variation in circulating transferrin receptor explained 61% of the variation in Hb level (P < .001). In 10 severely anemic patients, amelioration of anemia following intravenous iron administration resulted in normalization of serum transferrin receptor. Defective iron supply to the erythron rather than blunted epo production is the major cause of the microcytic anemia associated with SoJCA. A true body-iron deficiency caused by decreased iron absorption likely complicates long-lasting inflammation in the most anemic children, and this can be recognized by high serum transferrin receptor levels. Although oral iron is of no benefit, intravenous iron saccharate is a safe and effective means for improving iron availability for erythropoiesis and correcting this anemia. Thus, while chronically high endogenous IL-6 levels do not appear to blunt epo production, they are probably responsible for the observed abnormalities in iron metabolism. Anemia of chronic disease encompasses a variety of anemic conditions whose peculiar features may specifically correlate with the type of cytokine(s) predominantly released.

[1]  M. Atkins,et al.  Interleukin-6-associated anemia: determination of the underlying mechanism. , 1995, Blood.

[2]  Pieter,et al.  Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. , 1995, Blood.

[3]  R. Caporali,et al.  Iron status in Still's disease , 1995, The Lancet.

[4]  A. Bernad,et al.  Interleukin-6 is required in vivo for the regulation of stem cells and committed progenitors of the hematopoietic system. , 1994, Immunity.

[5]  S. Jacobsen,et al.  Distinct and direct synergistic effects of IL-1 and IL-6 on proliferation and differentiation of primitive murine hematopoietic progenitor cells in vitro. , 1994, Experimental hematology.

[6]  H. Groen,et al.  Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. , 1994, Blood.

[7]  N. E. Hansen,et al.  Serum transferrin receptor levels in anaemic patients with rheumatoid arthritis. , 1994, Scandinavian journal of clinical and laboratory investigation.

[8]  Y. Kohgo,et al.  Regulation of iron metabolism in HepG2 cells: A possible role for cytokines in the hepatic deposition of iron , 1993, Hepatology.

[9]  J. Bergström,et al.  New aspects of erythropoietin treatment , 1993, Journal of internal medicine.

[10]  E. Frenkel,et al.  Evaluation of bone marrow iron stores in anemia associated with chronic disease: A comparative study of serum and red cell ferritin , 1993, American journal of hematology.

[11]  S. Krantz,et al.  Progress in understanding the pathogenesis of the anemia of chronic disease. , 1992, Blood.

[12]  S. Albani,et al.  Serum interleukin-6 levels and joint involvement in polyarticular and pauciarticular juvenile chronic arthritis. , 1992, Clinical and experimental rheumatology.

[13]  M. Goldberg,et al.  EFFECT OF INFLAMMATORY CYTOKINES ON HYPOXIA-INDUCED ERYTHROPOIETIN PRODUCTION , 1992 .

[14]  E. Dessypris,et al.  Inhibition of human erythroid colony‐forming units by interleukin‐1 is mediated by gamma interferon , 1992, Journal of cellular physiology.

[15]  A. Martini,et al.  Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. , 1991, Arthritis and rheumatism.

[16]  C. Salvarani,et al.  Recombinant human erythropoietin therapy in patients with rheumatoid arthritis with the anemia of chronic disease. , 1991, The Journal of rheumatology.

[17]  T. Schnitzer,et al.  Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. , 1990, The American journal of medicine.

[18]  A. Nienhuis,et al.  Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. , 1990, The Journal of clinical investigation.

[19]  S. Kashiwazaki,et al.  Suppressed serum erythropoietin response to anemia and the efficacy of recombinant erythropoietin in the anemia of rheumatoid arthritis. , 1990, The Journal of rheumatology.

[20]  P. Furmanski,et al.  In vivo hematopoietic effects of recombinant interleukin-1 alpha in mice: stimulation of granulocytic, monocytic, megakaryocytic, and early erythroid progenitors, suppression of late-stage erythropoiesis, and reversal of erythroid suppression with erythropoietin. , 1989, Blood.

[21]  M. Hochberg,et al.  Serum immunoreactive erythropoietin in rheumatoid arthritis: impaired response to anemia. , 1988, Arthritis and rheumatism.

[22]  F. Houssiau,et al.  Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. , 1988, Arthritis and rheumatism.

[23]  H. Julius,et al.  Decreased iron absorption in patients with active rheumatoid arthritis, with and without iron deficiency. , 1988, Annals of the rheumatic diseases.

[24]  M. Cazzola,et al.  Adequacy of iron supply for erythropoiesis: in vivo observations in humans. , 1987, The Journal of laboratory and clinical medicine.

[25]  E. Goldwasser,et al.  Blunted erythropoietin response to anaemia in rheumatoid arthritis , 1987, British journal of haematology.

[26]  Ansell Bm,et al.  Microcytic anaemia in juvenile chronic arthritis. , 1987 .

[27]  N. E. Hansen,et al.  Serum ferritin as indicator of iron responsive anaemia in patients with rheumatoid arthritis. , 1986, Annals of the rheumatic diseases.

[28]  D. P. Bentley,et al.  Parenteral iron therapy in the anaemia of rheumatoid arthritis. , 1982, Rheumatology and rehabilitation.